Zevra Therapeutics (ZVRA) Stock Price, News & Analysis

Company Overview

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Key Stats

• Today's Range: $9.34 to $9.75
• 50-Day Range: $9.51 to $14.75
• 52-Week Range: $7.16 to $15.03
• Volume: 971,083 shs
• Average Volume: 1.54 million shs
• Market Capitalization: $562.23 million
• P/E Ratio: 4.78
• Dividend Yield: N/A
• Price Target: $26.86
• Consensus Rating: Moderate Buy

Zevra Therapeutics Stock Analysis - MarketRank™

Zevra Therapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 115th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Zevra Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 9 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Zevra Therapeutics has a consensus price target of $26.86, representing about 182.4% upside from its current price of $9.51.

Amount of Analyst Coverage

Zevra Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 26.79%

Earnings Growth

Earnings for Zevra Therapeutics are expected to grow by 26.79% in the coming year, from $0.56 to $0.71 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zevra Therapeutics is 4.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.13.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zevra Therapeutics is 4.78, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 221.81.

Price to Book Value per Share Ratio

Zevra Therapeutics has a P/B Ratio of 3.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.51% of the float of Zevra Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Zevra Therapeutics has a short interest ratio ("days to cover") of 5.44.

Change versus previous month

Short interest in Zevra Therapeutics has recently increased by 20.12%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zevra Therapeutics does not currently pay a dividend.

Dividend Growth

Zevra Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.05

News Sentiment

Zevra Therapeutics has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Zevra Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 6 people have searched for ZVRA on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

MarketBeat Follows

4 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zevra Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.40% of the stock of Zevra Therapeutics is held by insiders.

Percentage Held by Institutions

35.03% of the stock of Zevra Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 8/01/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ZVRA
• CIK: 1434647
• Web: www.kempharm.com
• Phone: (321) 939-3416
• Fax: 319-665-2577
• Employees: 20
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Zevra Therapeutics: $26.86
• High Price Target: $35.00
• Low Price Target: $20.00
• Potential Upside/Downside: +182.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.99
• Trailing P/E Ratio: 4.78
• Forward P/E Ratio: 16.98
• P/E Growth: N/A
• Net Income: $83.23 million
• Net Margins: 101.58%
• Pretax Margin: 109.08%
• Return on Equity: 51.49%
• Return on Assets: 28.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.89
• Quick Ratio: 4.84

Sales & Book Value

• Annual Sales: $106.47 million
• Price / Sales: 5.28
• Cash Flow: $0.95 per share
• Price / Cash Flow: 10.05
• Book Value: $2.75 per share
• Price / Book: 3.46

Miscellaneous

• Outstanding Shares: 59,120,000
• Free Float: 57,696,000
• Market Cap: $562.23 million
• Optionable: Optionable
• Beta: 0.85